Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Abstract

First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).

Keywords

Affiliated Institutions

• Assistance Publique Hôpitaux de Marseille FR
• Sotiria General Hospital GR
• Aix-Marseille Université FR
• Université de Limoges FR
• Emory University US
• Institut Català d'Oncologia ES
• Samsung Medical Center KR
• Hospital Universitari Germans Trias i Pujol ES
• Hospital Universitario Virgen del Rocío ES
• Saitama Cancer Center JP
• Bristol-Myers Squibb (United States) US
• Instituto Jalisciense de Cancerología MX
• Centre de Recherche en Cancérologie de Marseille FR
• Centro de Investigación Biomédica en Red de Cáncer ES
• Spanish National Cancer Research Centre ES
• Fox Chase Cancer Center US
• Cancer Institute (WIA) IN
• Sidney Kimmel Cancer Center US
• Hospital Italiano de Buenos Aires AR
• Institutul Oncologic Bucuresti RO
• University Hospital of Lausanne CH
• Memorial Sloan Kettering Cancer Center US
• Sungkyunkwan University KR
• National and Kapodistrian University of Athens GR
• LungenClinic Grosshansdorf DE
• Princess Alexandra Hospital AU
• Asan Medical Center KR

Related Publications